Actively Recruiting
Study of SAMe Supplement to Improve Liver Function in Adults With Alcoholic Cirrhosis Randomized, Placebo-Controlled Trial Including Healthy Non-Drinking Controls
Led by Indiana University · Updated on 2026-03-31
196
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of SAMe S-adenosylmethionine supplementation compared to placebo in patients with alcoholic cirrhosis classified as Child Class A or B. The study aims to test whether SAMe can improve liver function and reduce all-cause mortality in these patients. This is a randomized, double-blind, placebo-controlled trial sponsored by Indiana University, focusing on adults aged 18 to 70 years with alcoholic liver disease. Participants will be assigned randomly to one of three groups those receiving a placebo, those receiving SAMe tablets at a dose of 1,200 mg daily two tablets in the morning before breakfast and one in the evening before dinner for 24 months, or non-drinking healthy controls. The study treatment period lasts for 24 months with close monitoring of liver and intestinal function. During the study, participants will undergo assessments for liver function, mortality, and several secondary measures including intestinal permeability, cellular stress markers, liver cancer development, and infections. These evaluations will be conducted from baseline through the 24-month period. The study also includes safety monitoring and long-term follow-up to observe the effects of the SAMe supplement on participants health outcomes.
CONDITIONS
Brief Title
SAMe Trial for Patients With Alcoholic Cirrhosis
Research Team
M
Maggie Hesler, B.S
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here